IRD
Opus Genetics Inc.

406
Mkt Cap
$168.27M
Volume
174,583.00
52W High
$2.59
52W Low
$0.65
PE Ratio
-1.42
IRD Fundamentals
Price
$2.38
Prev Close
$2.44
Open
$2.46
50D MA
$2.03
Beta
1.00
Avg. Volume
496,847.53
EPS (Annual)
-$2.15
P/B
26.39
Rev/Employee
$610,666.67
Loading...
Loading...
News
all
press releases
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock
Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) Director Fighting Blindness Foundation sold 4,000,000 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Investment analysts at Brookline Capital Management issued their FY2025 earnings per share estimates for shares of Opus Genetics in a research note...
MarketBeat·8d ago
News Placeholder
Opus Genetics, Inc. $IRD is BIOS Capital Management LP's 2nd Largest Position
BIOS Capital Management LP lifted its stake in Opus Genetics, Inc. (NASDAQ:IRD - Free Report) by 270.1% during the 2nd quarter, according to the company in its most recent disclosure with the...
MarketBeat·18d ago
News Placeholder
Opus Genetics FY2025 EPS Forecast Lifted by HC Wainwright
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings estimates for Opus Genetics in a research report issued on Thursday, November 13th...
MarketBeat·25d ago
News Placeholder
FY2025 Earnings Estimate for Opus Genetics Issued By Wedbush
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at Wedbush boosted their FY2025 earnings per share estimates for Opus Genetics in a research report issued on Wednesday, November...
MarketBeat·25d ago
News Placeholder
HC Wainwright Comments on Opus Genetics Q1 Earnings
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Opus Genetics in a report released on Thursday, November 13th. HC...
MarketBeat·27d ago
News Placeholder
Opus Genetics (NASDAQ:IRD) Earns "Buy" Rating from Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $9.00 target price on shares of Opus Genetics in a research report on Thursday...
MarketBeat·28d ago
News Placeholder
Opus Genetics (NASDAQ:IRD) Posts Earnings Results, Misses Expectations By $0.11 EPS
Opus Genetics (NASDAQ:IRD - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.11). The...
MarketBeat·29d ago
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Opus Genetics, Inc. Q3 Loss Misses Estimates
(RTTNews) - Opus Genetics, Inc. (IRD) released Loss for third quarter that missed the Street estimates...
Nasdaq News: Markets·1mo ago

Latest IRD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.